Results 61 to 70 of about 1,641,713 (205)
Purpose To evaluate a minimum 5‐year follow‐up of patients who were treated with either bipolar radiofrequency microtenotomy (RFM) or physical therapy (PT) for midportion Achilles tendinopathy between 2016 and 2018. Methods All subjects who participated in a previous randomized controlled trial (n = 38) between 2016 and 2018 were invited to fill out a ...
Hayat Jirde Ali +3 more
wiley +1 more source
Although calcitonin gene-related peptide is a recognized pain transducer, the expression of calcitonin gene-related peptide in primary afferents may be differentially affected following different types of nerve injury. Here, we examined whether different
Yu Zou PhD +6 more
doaj +1 more source
Calcitonin and calcitonin gene-related peptide stimulate adenylate cyclase activity and plasminogen activator production in cultured renal tubular LLC-PK1 cells.
Fischer, J. A. +11 more
core +1 more source
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu +13 more
wiley +1 more source
Adrenomedullin selectivity of calcitonin-like receptor/receptor activity modifying proteins.
Co-expression of an initially orphan calcitonin receptor-like (CL)1 receptor with individual receptor-activity-modifying proteins (RAMP)1, -2 and -3 results in CL receptor/RAMP1, -2 and -3 proteins at the cell surface.
Born W +5 more
core +1 more source
Association study of the calcitonin gene-related polypeptide-alpha (CALCA) and the receptor activity modifying 1 (RAMP1) genes with migraine [PDF]
Migraine is a common neurovascular brain disorder characterised by recurrent attacks of severe headache that may be accompanied by various neurological symptoms.
Sutherland, H.G. +13 more
core +1 more source
Possible sites of action of the new calcitonin gene-related peptide receptor antagonists
Migraine is considered a neurovascular disease affecting more than 10% of the general population. Currently available drugs for the acute treatment of migraine are vasoconstrictors, which have limitations in their therapeutic use.
Sajedeh Eftekhari, Lars Edvinsson
doaj +1 more source
Neurovascular coupling in bone regeneration: Mechanisms, advanced biomaterials and challenges
This figure illustrates various material strategies for neurovascularized bone regeneration, including electroactive scaffolds, ion‐loaded materials, drug delivery systems, surface modifications, cells/cell products, growth factors, and peptides. These approaches aim to synergistically promote the regeneration of neural, vascular, and bone tissues ...
Yixin Ma +8 more
wiley +1 more source
Calcitonin gene‐related peptide (CGRP) in epilepsy: Mechanistic insights from preclinical models
Abstract Calcitonin gene‐related peptide (CGRP) is a pleiotropic neuropeptide widely expressed in the central and peripheral nervous systems, with established roles in neurovascular regulation, synaptic transmission, and neuroinflammation. While CGRP has been extensively characterized in migraine pathophysiology, its role in epilepsy remains ...
Marina Romozzi +8 more
wiley +1 more source
Abstract Migraine and epilepsy frequently coexist, but evidence on the safety of calcitonin gene‐related peptide (CGRP)‐targeting therapies in people with epilepsy is lacking. We evaluated long‐term migraine and epilepsy outcomes in a real‐world multicenter retrospective cohort of adults with comorbid migraine and epilepsy treated with anti‐CGRP ...
Marina Romozzi +13 more
wiley +1 more source

